Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study

Outcomes for children with relapsed or refractory acute myeloid leukaemia remain poor. The BCL-2 inhibitor, venetoclax, has shown promising activity in combination with hypomethylating agents and low-dose cytarabine in older adults for whom chemotherapy is not suitable with newly diagnosed acute mye...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 21; no. 4; pp. 551 - 560
Main Authors:	Karol, Seth E, Alexander, Thomas B, Budhraja, Amit, Pounds, Stanley B, Canavera, Kristin, Wang, Lei, Wolf, Joshua, Klco, Jeffery M, Mead, Paul E, Das Gupta, Soumyasri, Kim, Su Y, Salem, Ahmed Hamed, Palenski, Tammy, Lacayo, Norman J, Pui, Ching-Hon, Opferman, Joseph T, Rubnitz, Jeffrey E
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.04.2020 Elsevier Limited
Subjects:	Acute myeloid leukemia Adolescent Antineoplastic Combined Chemotherapy Protocols - administration & dosage Bcl-2 protein Bone marrow Bridged Bicyclo Compounds, Heterocyclic - administration & dosage Chemotherapy Child Child, Preschool Children Colitis Cytarabine Cytarabine - administration & dosage Female Fungal infections Hematology Hematology, Oncology, and Palliative Medicine Humans Idarubicin - administration & dosage Intravenous administration Invasiveness Leukemia Leukemia, Myeloid, Acute - drug therapy Male Neoplasm Recurrence, Local - drug therapy Neutropenia Neutrophils Patients Remission Sepsis Stem cells Sulfonamides - administration & dosage Transplants & implants Young Adult United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!